From Financial Modeling Prep: 2024-12-15 16:00:03

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) focuses on cardiovascular disease therapies with heavy R&D investments. It has a -44.65% ROIC and 5.55% WACC, indicating it’s not exceeding its cost of capital. ProKidney Corp. (NASDAQ:PROK) shows a 16.10% ROIC and 10.15% WACC, showcasing efficient capital utilization in the biopharmaceutical industry. Other peers also have negative ROIC to WACC ratios, highlighting the sector’s high-risk, high-reward nature.



Read more at Financial Modeling Prep:: NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Inv…